Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 20/20 | 0.50 |
| ▸ | CBL | P22681 | 18/20 | 0.47 |
| ▸ | CBLC | Q9ULV8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31251410 | 0.73 | CBLB (0.72) | CBLBCBLCBLC | |
| SCHEMBL30311255 | 0.72 | CBLB (0.78) | CBLBCBLCBLC | |
| SCHEMBL31251296 | 0.70 | CBLB (0.76) | CBLBCBLCBLC | |
| SCHEMBL31251286 | 0.69 | CBLB (0.67) | CBLBCBLCBLC | |
| SCHEMBL30938785 | 0.68 | CBLB (0.53) | CBLBCBLCBLC | |
| SCHEMBL31251484 | 0.68 | CBLB (0.67) | CBLBCBLCBLC | |
| SCHEMBL31251309 | 0.68 | CBLB (0.67) | CBLBCBLCBLC | |
| SCHEMBL31251432 | 0.67 | CBLB (0.69) | CBLBCBLCBLC | |
| SCHEMBL30311530 | 0.67 | CBLB (0.63) | CBLBCBLCBLC | |
| SCHEMBL31115401 | 0.66 | CBLB (0.63) | CBLBCBLCBLC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042896-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-02-06 | — | — | US | disclosed |
| CN-118139856-A | Parallel-ring compounds as Cbl-b inhibitors | 海南先声再明医药股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042896-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | CBLB, CBL, CBLC | CBLB 1/4885CBL 2/4885CBLC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.